Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

FDA Sets June Date to Hear Genentech's Arguments for Use of Avastin in Breast Cancer

TOP - Daily published on February 24, 2011
The US Food and Drug Administration (FDA) has agreed to hold a two-day hearing to give Genentech an opportunity to convince the agency not to revoke Avastin's (bevacizumab's) indication in breast cancer. Controversy raged among patients, medical professionals, and politicians from the moment the FDA announced last year that it was considering withdrawing its approval of Avastin to treat metastatic breast cancer.
 
Approval had been granted on an accelerated basis, with full approval pending additional confirmatory data. In a 12-to-1 decision, an Oncologic Drugs Advisory Committee (ODAC) concurred with the FDA that follow-up studies failed to show enough improvement in overall survival or progression-free survival for patients with breast cancer to justify the risks associated with the drug.
 
Genentech criticized the makeup of the ODAC panel as having too few breast cancer experts to make an informed decision. Following the FDA's announcement, the company requested a hearing before a new panel.
 
In a letter to Genentech's lawyers, dated February 23, 2011, Dr Karen Midthun, the FDA officer overseeing the hearing, said the agency is using the same panel but will allow Genentech to present its own experts on day one of the hearing. Witnesses testifying on behalf of the Center for Drug Evaluation and Research (CDER) will receive equal time. The public has been invited to submit written testimony. On day two of the hearing, the ODAC panel will present its conclusions. FDA commissioner Dr Margaret Hamburg will make the final ruling.
 
Prior to the hearing, Midthun wants Genentech and CDER to outline all disputed issues in a joint statement and submit this list to the FDA in mid-March. By April 20, 2011, each side must provide a summary of their respective arguments and evidence to the FDA. Midthun said all documents and testimony available to the public.
 

The United Kingdom's National Institute for Health and Clinical Excellence declined today to approve Avastin for metastatic breast cancer. The regulatory agency said evidence for the drug's effectiveness in improving overall survival "was not robust" and concluded that the drug was not cost-effective.
Related Items
A Review of Investigational Drugs at HOPA
Christin Melton
TOP - MAY 2011, VOL 4, NO 3 published on May 11, 2011 in Conference Correspondent
Review of New Oncology Drugs at HOPA
Christin Melton
TOP - March/April 2011, VOL 4, NO 2 published on April 28, 2011 in Conference Correspondent
Cost-Containment Strategies
Christin Melton
TOP - March/April 2011, VOL 4, NO 2 published on April 28, 2011 in Conference Correspondent
Making Cancer Drugs Worth the Cost
Christin Melton
TOP - March/April 2011, VOL 4, NO 2 published on April 28, 2011
Are You Talking to Patients About Smoking Cessation?
Christin Melton
TOP - March/April 2011, VOL 4, NO 2 published on April 28, 2011 in Conference Correspondent
Drug Shortages: A Growing Crisis in Oncology
Christin Melton
TOP - March/April 2011, VOL 4, NO 2 published on April 28, 2011 in Drug Updates
FDA Panel Recommends Stricter Process for Accelerated Approval of Cancer Drugs
Christin Melton
TOP - March/April 2011, VOL 4, NO 2 published on April 28, 2011 in In the News
Ipilimumab (Yervoy) Is First Melanoma Drug Approved in a Decade
Christin Melton
TOP - March/April 2011, VOL 4, NO 2 published on April 28, 2011 in Skin Cancer
Considerations for Cancer Treatment–Induced Diarrhea
Christin Melton
TOP - March/April 2011, VOL 4, NO 2 published on April 28, 2011 in Supportive Care
Managing Elderly Patients Who Have Comorbidities
Christin Melton
TOP - March/April 2011, VOL 4, NO 2 published on April 28, 2011 in Supportive Care
Last modified: July 22, 2021